TY - JOUR
T1 - Implementation strategies for high impact nephrology trials
T2 - the end of the trial is just the beginning
AU - Reidlinger, Donna M.
AU - Johnson, David W.
AU - Craig, Jonathan C.
AU - McDonald, Stephen P.
AU - Mallard, Alistair R.
AU - Robison, Laura E.
AU - Wong, Germaine
AU - Hawley, Carmel M.
PY - 2022/12
Y1 - 2022/12
N2 - There remains wide variation in treatment patterns and outcomes for kidney patients, and nephrology continues to lag behind other medical specialties in the number and quality of randomized controlled trials (RCTs).1 As currently conducted, RCTs require substantial investment in time and resources with enormous effort poured into trial design, funding, partnerships, data acquisition, analysis, and publications. Less attention is paid to activities to maximize practice and policy impact, and evaluation of evidence uptake commonly occurs only through the narrow lens of output metrics in peer-reviewed literature.
AB - There remains wide variation in treatment patterns and outcomes for kidney patients, and nephrology continues to lag behind other medical specialties in the number and quality of randomized controlled trials (RCTs).1 As currently conducted, RCTs require substantial investment in time and resources with enormous effort poured into trial design, funding, partnerships, data acquisition, analysis, and publications. Less attention is paid to activities to maximize practice and policy impact, and evaluation of evidence uptake commonly occurs only through the narrow lens of output metrics in peer-reviewed literature.
KW - clinical trials
KW - healthcare systems
KW - implementability
KW - knowledge translation
KW - research waste
UR - http://www.scopus.com/inward/record.url?scp=85138591065&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2022.07.006
DO - 10.1016/j.kint.2022.07.006
M3 - Article
C2 - 35926657
AN - SCOPUS:85138591065
SN - 0085-2538
VL - 102
SP - 1222
EP - 1227
JO - Kidney International
JF - Kidney International
IS - 6
ER -